GH Synergy Stack

The GH Synergy Stack combines two growth hormone secretagogues that target distinct receptor systems in the anterior pituitary. Sermorelin — a synthetic 29-amino acid analogue of growth hormone-releasing hormone (GHRH) — binds to GHRH receptors and stimulates the pituitary to release GH in a physiological, pulsatile pattern that mirrors endogenous hypothalamic signaling [PMID: 18031173]. Ipamorelin, a synthetic pentapeptide and selective ghrelin receptor agonist (GHSR-1a), triggers GH release through a separate receptor pathway while notably not elevating cortisol or prolactin — a selectivity that distinguishes it from earlier growth hormone-releasing peptides such as GHRP-6 and GHRP-2 [PMID: 9849822].

What makes this combination of scientific interest is the well-documented synergistic interaction between GHRH and ghrelin pathways. Research has shown that co-activation of GHRH and GHS receptors produces a cAMP response approximately twice that observed after activation of the GHRH receptor alone [PMID: 12446584]. In human studies, even low doses of ghrelin have been demonstrated to stimulate GH release synergistically with GHRH administration [PMID: 11549707]. This dual-pathway approach leads researchers to hypothesize that combining a GHRH analogue with a selective ghrelin mimetic may produce greater and more sustained GH elevation than either compound used independently.

Both compounds are classified as research peptides with evidence drawn from preclinical models and limited human studies. No large-scale clinical trials have established the long-term efficacy or safety of this specific combination. The information on this page reflects the published scientific literature as a resource for researchers — not guidance for human use, medical treatment, or diagnosis.

Sermorelin acts as a direct agonist at the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary. Research in elderly men demonstrated that sermorelin administration increased 24-hour mean GH, peak GH, and IGF-1 levels, with a 16-week study reporting increases of up to 107% in GH levels accompanied by corresponding IGF-1 elevation [PMID: 9141536]. Additional studies have shown that sermorelin promotes lean body mass gains (1.26 kg increase in men) and increased skin thickness, effects consistent with enhanced GH-IGF-1 axis activity [PMID: 9141536]. Importantly, sermorelin preserves the physiological pulsatility of GH secretion — unlike exogenous GH replacement, which produces sustained supraphysiological levels [PMID: 18046908].

Ipamorelin operates through a completely separate receptor mechanism. As a selective agonist at the ghrelin receptor (GHSR-1a), it stimulates GH release via phospholipase C activation and intracellular calcium signaling [PMID: 9849822]. The defining pharmacological feature of ipamorelin — reported in the landmark Raun et al. study — is its selectivity: it releases GH with potency comparable to GHRP-6 but without measurably elevating ACTH, cortisol, or prolactin, even at doses 200-fold above the effective dose [PMID: 9849822]. Pharmacokinetic modeling has shown ipamorelin produces a single episode of GH release with a peak at approximately 0.67 hours and an exponential decline, preserving the natural pulsatile pattern [PMID: 10496658].

The scientific rationale for combining these peptides rests on receptor-level synergy. Co-activation of GHRH and GHS receptors produces intracellular cAMP levels approximately twice those observed with GHRH receptor activation alone [PMID: 12446584]. This occurs because the two receptor systems activate distinct but complementary intracellular cascades — GHRH receptors via adenylyl cyclase and cAMP, GHS receptors via phospholipase C and diacylglycerol — that converge on GH vesicle exocytosis. In human studies, even sub-threshold doses of ghrelin produced synergistic GH release when combined with GHRH [PMID: 11549707].

No direct clinical trial has tested this specific combination in humans at therapeutic doses. The synergy rationale is extrapolated from receptor pharmacology studies and independent clinical data on each compound. Researchers should treat the evidence as mechanistically grounded but clinically unverified.

Both sermorelin and ipamorelin are studied via subcutaneous injection, which simplifies combined protocol design compared to stacks requiring different administration routes. However, the two compounds differ in their pharmacokinetic profiles and typical dosing patterns.

Sermorelin has a short half-life (typically 12–15 minutes) and is commonly studied at doses of 200–500 mcg per injection, administered once or twice daily. Research suggests that twice-daily dosing significantly raises IGF-1 levels more effectively than once-nightly dosing, indicating that frequency of administration is a critical variable [PMID: 32257855]. The subcutaneous route produces a rapid GH pulse within 15–30 minutes of administration.

Ipamorelin is typically studied at doses of 200–300 mcg per injection, administered once to three times daily. Its short half-life (approximately 2 hours) means that the GH pulse it produces is transient — a feature that researchers consider beneficial because it preserves physiological pulsatility rather than producing sustained GH elevation [PMID: 9849822].

Research protocols with individual GH secretagogues have been explored across durations of 4 to 16 weeks. Some researchers have described co-administering both peptides at the same time to maximize the synergistic pulse, while others stagger injections to produce more frequent GH episodes throughout the day. No consensus protocol exists for this specific combination, and all available information reflects either preclinical models, receptor pharmacology studies, or limited human data on individual compounds. As with all research peptides, no established human safety profile exists for this combination.